ClinicalTrials.gg
RecruitingNCT07229638Updated Mar 20, 2026

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

A Phase 1/2 interventional study of SHR-9839(sc) For Injection in Solid Tumor, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is an open-label, multi-center Phase IB/II clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide , has signed the IRB/EC-approved informed consent form with the date indicated, and is willing and able to comply with treatment plan visits, examinations, and other procedural requirements;
  2. Age 18-70 years (inclusive) at the time of signing the informed consent form, no gender restriction;
  3. performance status of 0 or 1;
  4. Expected survival ≥12 weeks;
  5. At least one according to v1.1 criteria;
  6. Subjects must provide formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimens. For subjects unable to provide tumor tissue as required, enrollment should be determined after discussion with the sponsor;
  7. Major organ function must meet standards (no use of blood components or growth factors within 14 days before the first dose to correct abnormalities); test results must be completed within 7 days prior to the first study treatment;
  8. Female subjects of must agree to use highly effective starting from the signing of the informed consent form, throughout the study treatment period, and for 9 months after the last administration of the product, and must avoid donating eggs during this period. Male subjects with partners of reproductive potential must agree to use highly effective contraception starting from the first dose of the investigational product, throughout the study treatment period, and for 6 months after the last administration of the investigational product, and must avoid donating sperm during this period. Female subjects must not be breastfeeding and must have a negative serum human chorionic gonadotropin (HCG) test within 7 days before the first dose (if the serum pregnancy test is positive, pregnancy must be excluded and enrollment confirmed after discussion with the sponsor).

Exclusion criteria

Exclusion Criteria:

  1. Patients with active central nervous system (CNS) or (including a history of such);
  2. Patients with other within 3 years before the first dose, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, locally resected prostate cancer, ductal carcinoma in situ post-surgery, or papillary thyroid carcinoma post-surgery (hormonal therapy for non-metastatic prostate or breast cancer is allowed);
  3. Patients deemed by the investigator to have uncontrolled tumor-related pain. Subjects requiring analgesic treatment must have a stable analgesic regimen before entering the study; symptomatic lesions suitable for palliative radiotherapy should be treated prior to study entry;
  4. Patients with severe cardiovascular or cerebrovascular disease;
  5. Patients with clinically symptomatic moderate or severe ascites (i.e., requiring therapeutic paracentesis or drainage within 2 weeks before the study treatment; subjects with only minimal ascites shown on imaging without clinical symptoms may be enrolled); uncontrolled or moderate-to-large pleural effusion or pericardial effusion;
  6. Patients with a history of interstitial pneumonia, including idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonia, radiation-induced pneumonia requiring treatment, or those with suspected interstitial pneumonia on imaging at screening, or in whom interstitial pneumonia cannot be excluded (subjects with only fibrotic radiation pneumonitis in the radiation field may participate); or patients with respiratory failure, severe asthma, severe , or other serious lung diseases significantly affecting pulmonary function; or those who have previously undergone total lung resection;
  7. Patients with severe infection within 4 weeks before the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infection complications requiring hospitalization; active infections of grade ≥2 requiring systemic antibiotic therapy within 2 weeks before the first dose; subjects receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection) may be enrolled;
  8. History of immunodeficiency, including positive test; presence of active (HBsAg positive during the screening period, and DNA quantification ≥1000 copies/ml or 500 IU/ml) or (anti-HCV positive and HCV RNA positive);
  9. Active pulmonary tuberculosis infection within one year prior to enrollment as indicated by medical history or imaging, or a history of active pulmonary tuberculosis more than one year ago that was not formally treated;
  10. Previous adverse reactions to anti-tumor treatments that have not recovered to CTCAE ≤ grade 1 (except for alopecia, grade 2 peripheral neuropathy meeting the enrollment criteria, or other situations judged by the investigator not to affect study drug treatment);
  11. Systemic anti-tumor treatment (including chemotherapy, biological therapy, targeted therapy, immunotherapy, radical radiotherapy, etc.) within four weeks prior to starting the study treatment;
  12. Chest radiotherapy >30 Gy within 24 weeks prior to first use of the study drug, non-chest radiotherapy >30 Gy within four weeks prior to first use (subjects who completed radiotherapy within 14 days prior to first dose may be enrolled), and palliative radiotherapy ≤30 Gy within 14 days prior to first use;
  13. Major organ surgery within 4 weeks prior to first use of the study drug (excluding ), significant trauma, or planned elective surgery during the trial; minor traumatic surgery (biopsy, endoscopy, and drainage procedures) within seven days prior to first use of the study drug;
  14. Within 3 months prior to the start of the study, participants who had intestinal obstruction or symptoms and signs of intestinal obstruction are excluded. However, if they have undergone surgical or other treatments and the obstruction has been completely relieved, they may be screened; those who have previously received intestinal stent placement and whose stent has not been removed by the screening period are also excluded;
  15. Severe gastrointestinal disorders, including but not limited to grade ≥2 inflammation, diarrhea, bleeding, obstruction, perforation, or fistula (except for hemorrhoidal bleeding or cases presenting only as positive fecal occult blood, which may be included);
  16. Use of within 28 days before the first administration of the study drug, or anticipated need for live attenuated vaccines during the study treatment;
  17. Pregnant or breastfeeding women, or women planning to become pregnant during the study period and within 7 months after the last administration of the study drug;
  18. History of severe allergic reactions to any component of the proposed study drug;
  19. According to the investigator's judgment, participants who have other factors that may affect the study results or potentially lead to premature termination of the study, such as alcoholism, drug abuse, other severe diseases (including psychiatric disorders) requiring concomitant treatment, severe laboratory abnormalities, domestic or social factors, and other circumstances that may impact participant safety or the collection of study data.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    SHR-9839(sc) combined with antitumor drugs, SHR-9839(sc) in different doses.

    Drug: SHR-9839(sc) For Injection

  • Experimental
    Treatment group B

    SHR-9839(sc) combined with antitumor drugs, SHR-9839(sc) in different doses.

    Drug: SHR-9839(sc) For Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (DLT)

    Time frame: 28 days.

  2. Adverse events (AEs)

    Time frame: 13 months.

  3. Recommended dose for expansion (RDE)

    Phase II.

    Time frame: From the first dose to the last visit, about 13 months.

  4. Objective Response Rate (ORR)

    Time frame: From the first dose to the last visit, about 13 months.

Secondary outcomes

  1. Disease control rate (DCR)

    Time frame: From the first dose to the last visit, about 13 months.

  2. Duration of response (DoR)

    Time frame: From the first dose to the last visit, about 13 months.

  3. Progression-Free Survival (PFS)

    Time frame: From the first dose to the last visit, about 13 months.

  4. Overall Survival (OS)

    Time frame: From the first dose to the last visit, about 13 months.

  5. Serious adverse events (SAEs)

    Time frame: From the first dose to the last visit, about 13 months.

07

Study locations

2 of 2 sites recruiting
  • The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Yanhong Gu · Contactguluer@163.com · +86-025-83714511
    • Yanhong Gu · Principal investigator
  • Fudan University Affiliated Cancer Hospital
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Sanjun Cai · Contactcaisanjuncsj@163.com · +86-021-64175590
    • Zhiyu Chen · Contactchenhj75@aliyun.com · +86-021-64175590
    • Sanjun Cai · Principal investigator
    • Zhiyu Chen · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Apr 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Feb 27, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jun 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07229638
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Feb 27, 2026
Primary completion
Apr 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Zhengjin Zhang
Contact
zhengjin.zhang.zz79@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-9839

Start the discussion